



OUR IMMUNOTHERAPY PRODUCTS ARE WELL POSITIONED IN RAPIDLY GROWING MARKETS WITH HIGH MEDICAL NEEDS.

About

NantKwest (Nasdaq: NK), is a pioneering, next generation, clinical-stage Immunotherapy company focused on harnessing the unique power of our Immune system using natural killer (NK) cells to treat cancer, infectious diseases and Inflammatory diseases. NK cells are the body's first line of defense due to the innate ability of NK cells to rapidly identify and destroy cells under stress, such as cancer or virally-infected cells.

NantKwest's unique NK cell based platform, with the capacity to grow active killer cells as a biological cancer therapy, has been designed to induce cell death against cancer or infected cells by three different modes of action:

- (1) Direct killing using activated NK cells (aNK) that release toxic granules directly into the cell through cell to cell contact,
- (2) Antibody-mediated killing using haNKs, which are NK cells engineered to incorporate a high affinity receptor that binds to an administered antibody, enhancing the cancer cell killing effect of that antibody, and
- (3) Target-activated killing using the taNK™ platform, which includes NK cells engineered to incorporate chimeric antigen receptors (CARs) to target tumor-specific antigens found on the surface of cancer cells

Our aNK, haNK® and taNK™ platform addresses certain limitations of T-cell therapies including the reduction of risk of serious "cytokine storms." As an "off-the-shelf" therapy, NantKwest's NK cells do not rely on a patient's own often compromised Immune system. In Phase 1 clinical trials in patients with late stage cancer, NantKwest's NK cells has been successfully administered as an outpatient infusion therapy without any reported severe side effects, even at doses of 10 billion cells.

By leveraging an integrated and extensive genomics and transcriptomics discovery and development engine, together with a pipeline of multiple, clinical-stage, immuno-oncology programs that include a phase 2 trial for a rare form of melanoma and the planned initiation of a clinical trial of NK cells targeted to breast cancer, we believe NantKwest is uniquely positioned to be the premier immunotherapy company and transform medicine by delivering living drugs in a bag and bringing novel NK cell-based therapies to routine clinical care.

[Learn more about our technology](#)